Labcorp Holdings Inc.

Labcorp Holdings Inc.

LHNYSE / NASDAQHealthcareLarge cap

$367.13-$1.75 (-0.5%)

Last close · Data as of Nov 20, 2026

Market cap
$21.4B
P/E
24.4x
EV / EBITDA
13.6x
Revenue
$14.0B
Net margin
6.3%
ROCE
9.4%

+40.4% over the last year

Labcorp Holdings Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+13.6%
3M
+10.3%
6M
+42.6%
1Y
+40.4%
5Y
+50.8%

52-week range

Day change -$1.75 (-0.5%) from $369 to $367 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in LH, bought on each weekday since 2021.

News & filings

What Labcorp Holdings filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthThe price is 24.5% above its 200-day average, and the 50-day average is above the 200-day.

Concerns (1)

  • Net profit fell 11.8% a year over three years.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services.

Read moreShow less

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Sector
Healthcare
Shares outstanding
82.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$21.4B
P/E
24.4x
P/B
2.5x
EV / EBITDA
13.6x
EV / Sales
2.0x
P/S
1.5x
52-week high
$372.46
52-week low
$250.39

Profitability

Operating margin
10.9%
Net margin
6.3%
EBITDA margin
14.4%
ROE
10.2%
ROCE
9.4%
ROA
4.8%
Asset turnover
0.76

Growth

Revenue
$14.0B
Revenue growth, 1Y
7.2%
Revenue CAGR, 3Y
5.6%
Net profit growth, 1Y
17.5%
Free cash flow
$1.2B

Solvency

Current ratio
1.42
Debt / Equity
0.76
Debt / Assets
0.35
CFO / Net profit
1.87
Cash / Market cap
2.5%

Where the revenue went

Of every $100 of FY2025 revenue, $6 was left as net income.

Labcorp Holdings Inc. income statement flow, FY2025
Labcorp Holdings Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$9.9B
RevenueGross profit$4.0B
Gross profitSelling, general and administrative$2.2B
Gross profitOther operating expenses$280.0M
Gross profitOperating income$1.5B
Operating incomePretax income$1.1B
Operating incomeInterest and other expense$408.7M
Pretax incomeTax and other$231.0M
Pretax incomeNet income$876.5M

Revenue and net profit

Revenue grew 7.2% in FY2025; net profit is the dashed line.

Labcorp Holdings Inc. revenue and net profit by fiscal year
Labcorp Holdings Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$11.9B$1.3B
FY2023$12.2B$418.0M
FY2024$13.0B$746.0M
FY2025$14.0B$876.5M

Cash flows

FY2025: $1.6B from operations, $1.2B free after investment (dashed).

Labcorp Holdings Inc. operating and free cash flow by fiscal year
Labcorp Holdings Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$2.0B$1.5B
FY2023$1.3B$874.1M
FY2024$1.6B$1.1B
FY2025$1.6B$1.2B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$14.0B+7.2%1Y
EBITDA
$2.0B+11.1%1Y
Net profit
$876.5M+17.5%1Y
Cash from operations
$1.6B+3.4%1Y
Free cash flow
$1.2B+10.0%1Y
Revenue CAGR, 3Y
5.6%
Net profit CAGR, 3Y
-11.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$14.0B$2.0B$876.5M$1.2B10.2%+7.2%+17.5%

Monthly returns

Month-by-month returns of LH across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$18.4B
Liabilities$9.8B
Equity$8.6B
Paid-in capital$0.00
Retained earnings$8.6B
Minority interest$16.9M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; LH highlighted.

P/E against peers

LH trades at 24.4x earnings against a peer median of 21.9x (a 12% premium).

Not shown (no positive earnings and no EV / Sales): Insmed Incorporated, Moderna, Inc., Viatris Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Labcorp Holdings Inc.LHthis companyP/E ↑ premium$21.4B24.4x2.5x10.2%13.6x
Mettler-Toledo International Inc.MTD$23.9B27.4x—-3676.8%20.9x
Insmed IncorporatedINSM$22.7B-17.8x30.8x-172.8%—
West Pharmaceutical Services, Inc.WST$22.4B45.4x7.1x15.5%28.4x
Quest Diagnostics IncorporatedDGX$21.7B21.9x3.0x13.8%12.9x
STERIS plcSTE$20.7B26.5x2.9x10.9%14.0x
Moderna, Inc.MRNA$20.5B-7.3x2.4x-32.6%-7.5x
Incyte CorporationINCY$20.2B15.7x3.9x24.9%9.8x
Viatris Inc.VTRS$18.5B—1.3x-23.9%—
Peer median—21.9x3.0x-6.5%13.5x

Year-to-date ROI

LH since 1 January, against earlier years.

Historical volatility

LH's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Labcorp Holdings Inc. operating margin by fiscal year
Labcorp Holdings Inc. operating margin by fiscal year
DateOperating margin
FY202214.8%
FY20239.2%
FY20248.7%
FY202510.9%
LineFY2025
Cost of revenueCost Of Revenue$9.9B
Gross profitGross Profit$4.0B
Operating expensesOperating Expense$2.5B
Selling, general and administrativeSelling General And Administration$2.2B
Depreciation and amortisationDepreciation And Amortization In Income Statement$280.0M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$280.0M
Amortization$280.0M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$280.0M
Total expensesTotal Expenses$12.4B
Pretax incomePretax Income$1.1B

Learn while you research

Academy chapters picked for Labcorp Holdings Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →